Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03219320 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
A Phase 2 study, sponsored by Aptinyx.
- Completed
- Registry status
- Phase 2
- Development phase
- 301
- Enrollment target
NCT03219320 is a Phase 2 study that has completed, run by Aptinyx. The registered enrollment target is 301 participants.
The verdict
NCT03219320, a Phase 2 study, has completed, sponsored by Aptinyx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 301 participants
- Enrollment target
Study Summary
To evaluate the efficacy of multiple dose levels of NYX-2925 versus placebo in treating the neuropathic pain associated with Diabetic Peripheral Neuropathy.
Interventions
- DRUG Placebo
- DRUG NYX-2925
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2017-06-27 |
| Est. Completion | 2018-11-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03219320
The ClinicalTrials.gov registry entry for NCT03219320 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aptinyx, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03219320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03219320 about?
NCT03219320 is a clinical study titled "Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy". To evaluate the efficacy of multiple dose levels of NYX-2925 versus placebo in treating the neuropathic pain associated with Diabetic Peripheral Neuropathy.
What is the current status of trial NCT03219320?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 301 participants. The study started on 2017-06-27. Estimated completion is 2018-11-02.
What interventions are being tested in trial NCT03219320?
The interventions under investigation include: Placebo (DRUG), NYX-2925 (DRUG).
Who is sponsoring clinical trial NCT03219320?
This trial is sponsored by Aptinyx, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.